What the labels record
Mounjaro® is a weekly tirzepatide injection for type 2 diabetes [1]. Its US label has no row for muscle pain, joint pain or body aches, either in the trial tables or among postmarketing reports [1]. The European product information and the Canadian monograph do not list them either [3][4].
The nearest entry is dysesthesia, meaning abnormal sensations in the skin. In the US placebo-controlled trials it was reported by 0.4% of people at each Mounjaro® dose and by no one on placebo; in the long cardiovascular trial, 0.7% reported it [1]. The European label classes it as uncommon, from postmarketing reports and that trial [3], and the Canadian patient information describes it as unusual skin sensations such as burning, tingling or pricking [4].
Soreness at the injection site is a separate, listed effect: injection site reactions occurred in 3.2% on Mounjaro® against 0.4% on placebo, and the EU label lists injection site pain as uncommon [1][3].
| Entry | What the source reports | Source |
|---|---|---|
| Muscle or joint pain | Not listed | US, EU and Canadian labels [1][3][4] |
| Dysesthesia (abnormal skin sensations) | Placebo 0%; 5, 10 and 15 mg 0.4% each; 0.7% in SURPASS-CVOT | US label, section 6.1 [1] |
| Dysaesthesia | Uncommon (≥1/1,000 to <1/100) | EU label, section 4.8 [3] |
| Injection site reactions | Placebo 0.4%; Mounjaro® 3.2% | US label, section 6.1 [1] |
What studies have looked at
A 2026 systematic review and meta-analysis in Drugs pooled 60 studies with over 1.2 million participants, covering GLP-1 medicines including tirzepatide [5]. It found no significant change in joint pain, stiffness or physical function on a standard osteoarthritis scale, and no clear effect on bone. It did find a decrease in lean body mass, mainly with liraglutide and semaglutide, with low certainty and largely explained by weight loss.
A 2026 analysis of FDA adverse event reports for incretin-based diabetes medicines found no musculoskeletal signal at the broad category level [6]. At the level of individual terms, GLP-1 medicines were linked in reports with back pain and muscle pain, and tirzepatide with muscle atrophy, with a median onset of 30 days or less. Reporting analyses cannot show cause or frequency.
Gout is a frequent question. In a post hoc analysis of SURMOUNT-1, a 72-week trial in 2,539 adults with obesity or overweight that excluded people with diabetes [12], all three tirzepatide doses lowered blood uric acid compared with placebo, and weight loss explained about 73% of the drop [7]. The analysis did not report gout attacks.
At the rare end, a 2026 report described a man whose muscle aches, fatigue and dark urine developed over two weeks after he had recently started tirzepatide; he was diagnosed with rhabdomyolysis and recovered after stopping it and receiving fluids [8]. One case cannot establish cause or frequency.
Possible links to Mounjaro®
Supported by the labels: injection-site soreness is a listed effect [1][3]. Abnormal skin sensations are listed as uncommon [3][4].
Plausible but not measured: Mounjaro® can cause vomiting and diarrhea, and the European label asks people to avoid fluid and electrolyte loss [3]. MedlinePlus lists electrolyte imbalance, such as low potassium or calcium, among causes of muscle pain, and severe dehydration among causes of rhabdomyolysis [9][11].
Uncertain: whether the reductions in lean mass seen with GLP-1 medicines translate into aches or weaker muscles has not been shown [5].
More common causes to rule out
MedlinePlus lists overuse, strain, tension and stress as the most common causes of muscle pain, followed by infections such as flu, autoimmune and inflammatory conditions, and medicines including statins for cholesterol and ACE inhibitors for blood pressure [9]. For joints, it adds osteoarthritis, rheumatoid arthritis, bursitis, tendinitis, viral infections and gout [10].
Medicines matter here because they are so common in type 2 diabetes. In SURPASS-CVOT, 86% of participants took a statin and 40% an ACE inhibitor at the start [1]. MedlinePlus advises contacting your provider when muscle pain is linked to starting or changing a medicine such as a statin [9].
New activity can also play a part: people who start exercising as their weight falls may feel the usual muscle soreness that comes with it.
What tends to help
For aches from overuse or strain, MedlinePlus suggests rest, ice in the first one to three days and heat after that, gentle stretching and massage, and returning to regular low-impact activity such as walking, cycling or swimming [9]. It mentions acetaminophen or ibuprofen for this kind of pain; ask a pharmacist which suits your kidneys and other medicines [9].
For non-arthritic joint pain, MedlinePlus describes rest balanced with exercise, warm baths and stretching [10]. Drinking enough fluids before and during exercise is part of its prevention advice for muscle aches [9].
Do not stop or change Mounjaro®, a statin or any other medicine because of aches without speaking to your prescriber.
Mounjaro® is a registered trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Muscle pain or weakness with dark, red or cola-coloured urine, or passing much less urine than usual | Emergency services or same-day care | Emergency | MedlinePlus [9][11]; case report [8] |
| Aches with a very stiff neck, high fever or vomiting, or trouble breathing or swallowing | Emergency services | Emergency | MedlinePlus [9]; Medication Guide [2] |
| A joint that is suddenly swollen, red, warm and very painful, or joint pain with fever | Your clinician | Today | MedlinePlus [10] |
| Muscle pain that began after starting or changing a statin or another medicine | Your prescriber | At your next appointment | MedlinePlus [9] |
| Burning, tingling or prickling skin, or aches lasting more than three days | Your prescriber | At your next appointment | Canadian monograph [4]; MedlinePlus [9] |
